Related Experiment Video

Updated: Mar 14, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

890

New twists in the AXL(e) of tumor progression

Balazs Halmos1, Eric B Haura2

  • 1Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USA. bahalmos@montefiore.org.

Science Signaling
|October 6, 2016
PubMed

Insights

The kinase AXL drives the mesenchymal gene signature and cell motility in ovarian cancer, contributing to poor prognosis. Targeting AXL may slow tumor progression in patients with this aggressive cancer subtype.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Mesenchymal subtype of ovarian cancer is associated with poor prognosis and limited treatment options.
  • Metastatic progression remains a significant challenge in managing ovarian cancer.

Purpose of the Study:

  • To investigate the role of the kinase AXL in driving the mesenchymal phenotype and motility of ovarian cancer cells.
  • To explore the potential of AXL as a therapeutic target for ovarian cancer.

Main Methods:

  • Analysis of gene expression patterns related to the mesenchymal phenotype.
  • Assessment of cell motility assays in ovarian cancer cell lines.
  • Evaluation of AXL's role in driving these cellular characteristics.

Main Results:

  • The kinase AXL was identified as a key driver of the mesenchymal gene signature in ovarian cancer cells.
  • AXL activity was found to promote the motility of these tumor cells.
  • AXL inhibition presents a potential strategy to impede tumor progression.

Conclusions:

  • AXL kinase is a critical mediator of the mesenchymal subtype in ovarian cancer.
  • Targeting AXL may offer a novel therapeutic approach to slow metastatic progression in patients with this ovarian cancer subtype.

More Related Videos

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

967
Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

11.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K